The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer
Open accessAbstract
Prostate cancer (CaP) progresses from prostatic intraepithelial neoplasia through locally invasive adenocarcinoma to castration-resistant metastatic carcinoma. Although radical prostatectomy, radiation and androgen ablation are effective therapies for androgen-dependent CaP, metastatic castration-resistant CaP is a major complication with high mortality. Androgens stimulate growth and survival of prostate epithelium and early CaP. Although most patients initially respond to androgen ablation, many develop castration-resistant CaP within 12–18 months. Despite extensive studies, the mechanisms underlying the emergence of castration-resistant CaP remain poorly understood and their elucidation is critical for developing improved therapies. Curiously, castration-resistant CaP remains androgen-receptor dependent, and potent androgen-receptor antagonists induce tumour regression in castrated mice. The role of inflammation in castration-resistant CaP has not been addressed, although it was reported that intrinsic NF-κB activation supports its growth. Inflammation is a localized protective reaction to injury or infection, but it also has a pathogenic role in many diseases, including cancer. Whereas acute inflammation is critical for host defence, chronic inflammation contributes to tumorigenesis and metastatic progression. The inflammation-responsive IκB kinase (IKK)-β and its target NF-κB have important tumour-promoting functions within malignant cells and inflammatory cells. The latter, including macrophages and lymphocytes, are important elements of the tumour microenvironment, but the mechanisms underlying their recruitment remain obscure, although they are thought to depend on chemokine and cytokine production. We found that CaP progression is associated with inflammatory infiltration and activation of IKK-α, which stimulates metastasis by an NF-κB-independent, cell autonomous mechanism. Here we show that androgen ablation causes infiltration of regressing androgen-dependent tumours with leukocytes, including B cells, in which IKK-β activation results in production of cytokines that activate IKK-α and STAT3 in CaP cells to enhance hormone-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Self-citationDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
Balkwill, F., Charles, K. A., & Mantovani, A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.013 · Cited by 1,769
Inducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641
Activation by IKKα of a Second, Evolutionary Conserved, NF-κB Signaling Pathway
Senftleben, U., Cao, Y., Xiao, G., Greten, F. R., Krähn, G., Bonizzi, G., Chen, Y., Hu, Y., Fong, A., Sun, S.-C., et al. (2001) · Science · doi:10.1126/science.1062677 · Cited by 1,359
Self-citationProstate cancer in a transgenic mouse.
Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., Matusik, R. J., & Rosen, J. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3439 · Cited by 1,294
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis
Kim, S., Takahashi, H., Lin, W.-W., Descargues, P., Grivennikov, S., Kim, Y., Luo, J.-L., & Karin, M. (2009) · Nature · doi:10.1038/nature07623 · Cited by 1,100
Self-citationInnate Immunity Gone Awry: Linking Microbial Infections to Chronic Inflammation and Cancer
Karin, M., Lawrence, T., & Nizet, V. (2006) · Cell · doi:10.1016/j.cell.2006.02.016 · Cited by 942
Self-citationLegler, D. F., Loetscher, M., Roos, R. S., Clark-Lewis, I., Baggiolini, M., & Moser, B. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.655 · Cited by 837
Myc-driven murine prostate cancer shares molecular features with human prostate tumors
Ellwood-Yen, K., Graeber, T. G., Wongvipat, J., Iruela-Arispe, M. L., Zhang, J., Matusik, R., Thomas, G. V., & Sawyers, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00197-1 · Cited by 816
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent
de Visser, K. E., Korets, L. V., & Coussens, L. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.014 · Cited by 715
Luo, J.-L., Maeda, S., Hsu, L.-C., Yagita, H., & Karin, M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.012 · Cited by 603
Self-citationSakurai, T., He, G., Matsuzawa, A., Yu, G.-Y., Maeda, S., Hardiman, G., & Karin, M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.016 · Cited by 487
Self-citationNuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin
Luo, J.-L., Tan, W., Ricono, J. M., Korchynskyi, O., Zhang, M., Gonias, S. L., Cheresh, D. A., & Karin, M. (2007) · Nature · doi:10.1038/nature05656 · Cited by 436
Self-citationFc‐Receptors as Regulators of Immunity
Nimmerjahn, F., & Ravetch, J. V. (2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)96005-8 · Cited by 418
Wu, X., Wu, J., Huang, J., Powell, W. C., Zhang, J., Matusik, R. J., Sangiorgi, F. O., Maxson, R. E., Sucov, H. M., & Roy-Burman, P. (2001) · Mechanisms of Development · doi:10.1016/s0925-4773(00)00551-7 · Cited by 390
Bonizzi, G., Bebien, M., Otero, D. C., Johnson‐Vroom, K. E., Cao, Y., Vu, D., Jegga, A. G., Aronow, B. J., Ghosh, G., Rickert, R. C., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600391 · Cited by 338
Self-citationPark, B. K., Zhang, H., Zeng, Q., Dai, J., Keller, E. T., Giordano, T., Gu, K., Shah, V., Pei, L., Zarbo, R. J., et al. (2007) · Nature Medicine · doi:10.1038/nm1519 · Cited by 325
Interleukin-6 and prostate cancer progression
SMITH, P., HOBISCH, A., LIN, D., CULIG, Z., & KELLER, E. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00021-6 · Cited by 264
Chen, T., Wang, L. H., & Farrar, W. L. (2000) · PubMed · Cited by 258
THE BIOLOGY OF HORMONE REFRACTORY PROSTATE CANCER
Isaacs, J. T. (1999) · Urologic Clinics of North America · doi:10.1016/s0094-0143(05)70066-5 · Cited by 251
Jin, R. J., Lho, Y., Connelly, L., Wang, Y., Yu, X., Saint Jean, L., Case, T. C., Ellwood-Yen, K., Sawyers, C. L., Bhowmick, N. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0107 · Cited by 182
Lee, Y., Chin, R. K., Christiansen, P., Sun, Y., Tumanov, A. V., Wang, J., Chervonsky, A. V., & Fu, Y.-X. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.016 · Cited by 174
Eriksen, K., Kaltoft, K., Mikkelsen, G., Nielsen, M., Zhang, Q., Geisler, C., Nissen, M., Röpke, C., Wasik, M., & Ødum, N. (2001) · Leukemia · doi:10.1038/sj.leu.2402093 · Cited by 162
Watson, P. A., Ellwood-Yen, K., King, J. C., Wongvipat, J., LeBeau, M. M., & Sawyers, C. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-3441 · Cited by 159
Wen, D., Nong, Y., Morgan, J. G., Gangurde, P., Bielecki, A., DaSilva, J., Keaveney, M., Cheng, H., Fraser, C., Schopf, L. R., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097584 · Cited by 126
Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting
Tumanov, A. V., Grivennikov, S. I., Shakhov, A. N., Александрович, Р. С., Koroleva, E. P., Takeda, J., Nedospasov, S. A., & Kuprash, D. V. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00071.x · Cited by 101
Self-citationStat3 as a Potential Target for Cancer Immunotherapy
Kortylewski, M., & Yu, H. (2007) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211327.76266.65 · Cited by 98
Hamel, K. M., Doodes, P. D., Cao, Y., Wang, Y., Martinson, J., Dunn, R., Kehry, M. R., Farkas, B., & Finnegan, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4994 · Cited by 85
CXCL13 neutralization reduces the severity of collagen‐induced arthritis
Zheng, B. Q., Özen, Z., Zhang, X., Silva, S. D., Marinova, E., Guo, L., Wansley, D. L., Huston, D. P., West, M. R., & Han, S. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20768 · Cited by 74
Rapid tolerization of virus-activated tumor-specific CD8 + T cells in prostate tumors of TRAMP mice
Bai, A., Higham, E. M., Eisen, H. N., Wittrup, K. D., & Chen, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805599105 · Cited by 67
Liu, X., Plummer, S. J., Nock, N. L., Casey, G., & Witte, J. S. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj294 · Cited by 66
Worm, M., Tsytsykova, A. V., & Geha, R. S. (1998) · European Journal of Immunology · Cited by 31
Treatment options for androgen-independent prostate cancer.
Gulley, J. L., Figg, W. D., & Dahut, W. L. (2003) · PubMed · Cited by 26
Cited by
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Self-citationZhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Self-citation
Metadata
- Authors
- Ammirante, M., Luo, J.-L., Grivennikov, S., Nedospasov, S., & Karin, M.
- Venue
- Nature
- Published
- 2010-03-11
- Volume
- 464
- Issue
- 7286
- Pages
- 302-305
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1969438318
- Cited by
- 639
- References
- 38
- FWCI
- 33.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.